Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism

• Main Authors: Isabel Elías (Author), Itziar Oyagüez (Author), Luis Antonio Alvarez-Sala (Author), Fernando García-Bragadoa (Author), Andrés Navarro (Author), Paloma González (Author), Fernando de Andrés-Nogales (Author), Javier Soto (Author)
• Format: Book
• Published: Elsevier, 2016-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Cost-effectiveness analysis of a 6-month treatment of apixaban (10 mg/12h, first 7 days; 5 mg/12h afterwards) for the treatment of the first event of venous thromboembolism (VTE) and prevention of recurrences, versus low-molecular-weight heparins/vitamin K antagonists treatment (LMWH/VKA)...